Wound Management Technologies, Inc. (OTCMKTS:WNDM) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement.
Wound Management Technologies, Inc. (OTCMKTS:WNDM) Files An 8-K Entry into a Material Definitive Agreement
On March 10, 2017, Wound Management Technologies, Inc. (the “Company”) and John Siedhoff, the chairman of the Company’s Board of Directors, entered into an amendment to the Consulting Agreement, dated April 25, 2016, by and between the Company and Mr. Siedhoff (the “Amendment”). The Amendment: (i) changes the name of the consultant under the Consulting Agreement from John Siedhoff to Twin Oaks Equities, LLC (an entity controlled by Mr. Siedhoff), and (ii) increases the monthly compensation payable under the Consulting Agreement from $15,000 to $20,000, effective as of January 1, 2017.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
Exhibit.
No.
Description
10.1
Amendment to Consulting Agreement dated March 10, 2017, by and between the Company and John Siedhoff
About Wound Management Technologies, Inc. (OTCMKTS:WNDM)
Wound Management Technologies, Inc., formerly MB Software, Inc., distributes collagen-based wound care products to healthcare providers, such as physicians, clinics and hospitals. The Company’s subsidiaries include Wound Care Innovations, LLC (WCI), Resorbable Orthopedic Products, LLC and Innovate OR, Inc. The Company’s WCI provides CellerateRX product in the wound care market. CellerateRX is a medical device for use on all acute and chronic wounds, except third degree burns. CellerateRX is offered in both gel and powder form. WCI expanded its CellerateRX product line to include CellerateRX Surgical products. Wound Management Technologies, Inc. (OTCMKTS:WNDM) Recent Trading Information
Wound Management Technologies, Inc. (OTCMKTS:WNDM) closed its last trading session up +0.0010 at 0.0740 with 269,104 shares trading hands.
Wound Management Technologies, Inc., formerly MB Software, Inc., distributes collagen-based wound care products to healthcare providers, such as physicians, clinics and hospitals. The Company’s subsidiaries include Wound Care Innovations, LLC (WCI), Resorbable Orthopedic Products, LLC and Innovate OR, Inc. The Company’s WCI provides CellerateRX product in the wound care market. CellerateRX is a medical device for use on all acute and chronic wounds, except third degree burns. CellerateRX is offered in both gel and powder form. WCI expanded its CellerateRX product line to include CellerateRX Surgical products. Wound Management Technologies, Inc. (OTCMKTS:WNDM) Recent Trading Information
Wound Management Technologies, Inc. (OTCMKTS:WNDM) closed its last trading session up +0.0010 at 0.0740 with 269,104 shares trading hands.